China Resources Boya Bio pharmaceutical Group Co Ltd (300294) — Financial Flexibility Index
China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has a Financial Flexibility Index of 0.14x as of December 2025. Free cash flow of CN¥159.28 Million (operating CF CN¥36.82 Million minus capex CN¥122.46 Million) represents 0% of total liabilities (CN¥1.16 Billion). Check total reinvestment intensity of China Resources Boya Bio pharmaceutical to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
China Resources Boya Bio pharmaceutical Group Co Ltd Financial Flexibility Index (2009–2025)
Historical Financial Flexibility Index trend for China Resources Boya Bio pharmaceutical Group Co Ltd across 17 annual periods. For the full cash flow conversion analysis, see China Resources Boya Bio pharmaceutical operating cash flow efficiency.
Annual Financial Flexibility Index for China Resources Boya Bio pharmaceutical Group Co Ltd (2009–2025)
Year-by-year free cash flow to debt coverage for China Resources Boya Bio pharmaceutical Group Co Ltd. Explore 300294 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.56x | CN¥651.99 Million | CN¥116.69 Million | CN¥1.16 Billion | ▲ +2.7% |
| 2024 | 0.54x | CN¥497.58 Million | CN¥299.78 Million | CN¥913.38 Million | ▼ -62.0% |
| 2023 | 1.44x | CN¥729.22 Million | CN¥641.73 Million | CN¥508.07 Million | ▲ +46.2% |
| 2022 | 0.98x | CN¥734.85 Million | CN¥596.44 Million | CN¥748.35 Million | ▼ -51.3% |
| 2021 | 2.02x | CN¥1.41 Billion | CN¥1.35 Billion | CN¥701.30 Million | ▲ +126.1% |
| 2020 | 0.89x | CN¥861.09 Million | CN¥718.58 Million | CN¥966.08 Million | ▲ +4464.1% |
| 2019 | -0.02x | CN¥-25.90 Million | CN¥-114.51 Million | CN¥1.27 Billion | ▼ -117.9% |
| 2018 | 0.11x | CN¥148.80 Million | CN¥34.90 Million | CN¥1.30 Billion | ▼ -36.7% |
| 2017 | 0.18x | CN¥213.97 Million | CN¥-23.82 Million | CN¥1.19 Billion | ▼ -89.6% |
| 2016 | 1.74x | CN¥498.84 Million | CN¥198.76 Million | CN¥287.30 Million | ▲ +58.7% |
| 2015 | 1.09x | CN¥306.39 Million | CN¥147.02 Million | CN¥280.11 Million | ▼ -39.5% |
| 2014 | 1.81x | CN¥169.78 Million | CN¥121.88 Million | CN¥93.90 Million | ▲ +133.9% |
| 2013 | 0.77x | CN¥122.00 Million | CN¥89.11 Million | CN¥157.85 Million | ▼ -82.9% |
| 2012 | 4.53x | CN¥116.81 Million | CN¥92.36 Million | CN¥25.80 Million | ▲ +210.7% |
| 2011 | 1.46x | CN¥99.79 Million | CN¥81.53 Million | CN¥68.48 Million | ▲ +132.0% |
| 2010 | 0.63x | CN¥61.42 Million | CN¥24.77 Million | CN¥97.79 Million | ▼ -11.1% |
| 2009 | 0.71x | CN¥107.28 Million | CN¥51.88 Million | CN¥151.93 Million | — |